Physician profile
Alan Simon
NPI 1316946270
$2,045.73
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $81.82 · 2021: $343 · 2022: $927 · 2023: $208 · 2024: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $263.00 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $238.94 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.77 | 2019-2024 | Jardiance |
| Amgen INC. | $181.93 | 2021-2024 | Repatha |
| Boston Scientific Corporation | $145.34 | 2019-2023 | Watchman Access System |
| Cvrx, INC. | $132.68 | 2021-2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $121.49 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $103.85 | 2021-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $84.37 | 2019-2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $81.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $79.54 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $67.31 | 2019-2024 | Farxiga |
| Abbott Laboratories | $50.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $44.16 | 2019-2022 | |
| Amarin Pharma, INC. | $41.95 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $25.89 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.66 | 2022 | |
| Heartflow, INC. | $21.36 | 2024 | |
| Irhythm Technologies, INC. | $20.96 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $18.08 | 2024 | Opsumit |
| Scpharmaceuticals INC. | $17.16 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.78 | 2024 | Arcalyst |
| Lundbeck LLC | $14.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.23 | 2022 | |
| Medicure Pharma INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.